<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797873</url>
  </required_header>
  <id_info>
    <org_study_id>2015/127-31/1_EI_ADHD</org_study_id>
    <nct_id>NCT02797873</nct_id>
  </id_info>
  <brief_title>Emotional and Non-emotional Regulation in Patients With Emotional Instability and ADHD</brief_title>
  <official_title>Emotional and Non-emotional Regulation in Patients With Emotional Instability Personality Disorder (EIP) and Attention Deficit Hyperactivity Disorder (ADHD) Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how emotional and non-emotional regulation&#xD;
      processes differ in EIP patients (with different levels of ADHD symptoms/ADHD-comorbidity)&#xD;
      compared to controls. The investigators will test these participants' abilities to regulate&#xD;
      emotional and non-emotional processes, reward anticipation and reward receipt while they&#xD;
      undergo functional magnetic resonance imaging (fMRI). The participants' motor inhibition&#xD;
      capacity on a behavioral level will also be investigated.&#xD;
&#xD;
      The hypothesis is that EIP patients will present with more deficits in emotion regulation&#xD;
      processes compared to controls, even when controlling for ADHD symptoms. It is also&#xD;
      hypothesized that higher levels of ADHD symptoms will correlate with dysfunctional&#xD;
      non-emotional regulation processes, on a behavioral as well as brain mechanistic level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Comorbidity of Emotional Instability Personality Disorder (EIP) and Attention&#xD;
      Deficit Hyperactivity Disorder (ADHD) is common, and the two patient groups partially exhibit&#xD;
      similar problems. The main hypothesis is that the two disorders are mechanistically related.&#xD;
      The investigators believe that the mechanisms underlying the problems are linked to two&#xD;
      parallel regulating systems in the brain. Here, prefrontal and anterior cingulate systems are&#xD;
      in focus. The first system - including the dorsolateral prefrontal cortex (dlPFC) and the&#xD;
      caudal anterior cingulate cortex (cACC) - regulates non-emotional (and exteroceptive)&#xD;
      information. The other system - including the lateral orbitofrontal prefrontal cortex (lObfc)&#xD;
      and rostral anterior cingulate cortex (rACC) - regulates emotional (and interoceptive)&#xD;
      information. The hypothesis is that the non-emotional/exteroceptive regulatory system is more&#xD;
      affected in ADHD, while the emotional/interoceptive regulatory system is more affected in&#xD;
      EIP.&#xD;
&#xD;
      Aims: The aim of this study is to differentiate between dysfunctional emotional regulation&#xD;
      processes related to emotional instability symptoms (when controlling for non-emotional&#xD;
      ADHD-like symptoms), and dysfunctional non-emotional regulation processes related to ADHD&#xD;
      symptoms (when controlling for emotional instability symptoms).&#xD;
&#xD;
      Procedure:&#xD;
&#xD;
        -  Participants: 30 young women from the Emotional Instability Unit at Child and Adolescent&#xD;
           Psychiatry in Stockholm (Dialectic Behavioral Therapy unit (&quot;DBT-teamet&quot;)), with traits&#xD;
           of emotional instability and with varying levels of ADHD symptoms. 30 matched healthy&#xD;
           controls.&#xD;
&#xD;
        -  Tests:&#xD;
&#xD;
      Behavioral task: Stop Signal Task: measures participant's ability to inhibit a motor&#xD;
      response. Outcome measures are Stop Signal Reaction Time (SSRT) and Go Reaction Time (GoRT)&#xD;
&#xD;
      fMRI task 1: Stroop task. Divided into 2 sessions of 10 minutes with 2 blocks in each. There&#xD;
      are two types of blocks: Emotional Stroop task blocks (happy or fearful faces, with the word&#xD;
      &quot;HAPPY&quot; or &quot;FEAR&quot; written across them) and Neutral Stroop task blocks (neutral faces of men&#xD;
      and women with the word &quot;MAN&quot; or &quot;WOMAN&quot; written across them). Every other block is Emotional&#xD;
      and every other is Neutral (balanced order between participants) so that each participant&#xD;
      performs two emotional blocks and two neutral blocks. The task is to decide what emotion or&#xD;
      gender is shown in the picture and ignore the word. Responses are made using a button box and&#xD;
      reaction time is recorded for all the trials. Blood Oxygen Level Dependent (BOLD) signal is&#xD;
      recorded in the brain during the task. Outcome measures are reaction times for the different&#xD;
      trial types (incongruent(I) and congruent(C), also order dependent) as well as BOLD signal&#xD;
      during these different types of trial.&#xD;
&#xD;
      fMRI task 2: Monetary Incentive Delay task (MID). Divided into 2 session of 10 minutes.&#xD;
      Reward task in which the participant may win money (0 Swedish kronor (SEK), 10 SEK or 50 SEK&#xD;
      in each trial). There is an anticipation phase in each trial, a response cue during which the&#xD;
      participant needs to press a button as fast as she can, and an outcome phase in which&#xD;
      feedback is presented of whether the participant has won the anticipated money or not.&#xD;
      Outcome measures are BOLD activation during the anticipation phases of different levels of&#xD;
      reward, and BOLD activation during the receipt/outcome phase of the different levels of&#xD;
      reward. Reaction times for the different reward levels are also recorded.&#xD;
&#xD;
      The overall step-by-step procedure for each participant:&#xD;
&#xD;
        -  Telephone screening (both participant and guardian): information about the study, MRI&#xD;
           safety screening, check initial inclusion/exclusion criteria are met.&#xD;
&#xD;
        -  Informed consent: sent by post to all legal guardians and the participant. Returned by&#xD;
           post to test leader.&#xD;
&#xD;
        -  The Strengths and Difficulties Questionnaire (SDQ) and socio-economic status&#xD;
           questionnaires sent to one legal guardian and returned to test leader upon completion.&#xD;
&#xD;
        -  Visit/Day 1: Assessment with questionnaires, interviews and behavioral testing (For&#xD;
           selection of participants: Structured Clinical Interview for Diagnostic and Statistical&#xD;
           Manual of Mental Disorders (DSM)-IV (SCID)-II interview Borderline and Antisocial parts,&#xD;
           SDQ, Adult Self-Report Scale (ASRS), Autism Spectrum Quotient (AQ), Toronto Alexithymia&#xD;
           Scale (TAS)-20, Ravens SPM, reading test, color vision test, questionnaire with&#xD;
           additional questions. For characterization of participants: Brown-Attention Deficit&#xD;
           Disorder (ADD), Mood and Feelings Questionnaire (MFQ), State and Trait Anxiety&#xD;
           Inventory-Trait (STAI-T), Barratt's Impulsivity Scale (BIS)). Frankfurter Test und&#xD;
           Training des Erkennens von fazialem Affekt (FEFA) 2 test (face recognition) and Stop&#xD;
           signal test (SST). Approximately 3 hours.&#xD;
&#xD;
        -  DAWBA computerized interview at home. Both participant and one legal guardian complete&#xD;
           this.&#xD;
&#xD;
        -  Additional information from patient records gathered, to verify current and previous&#xD;
           diagnoses.&#xD;
&#xD;
        -  Visit/Day 2: Assessments with questionnaires (STAI-S, last menstruation, sleepiness&#xD;
           rating, motivation rating). MRI-scan: session 1: T1, Stroop session 1, Stroop session 2,&#xD;
           T2. Break. Session 2: MID session 1, MID session 2. Break. Session 3: resting state,&#xD;
           DTI. Assessments after scan: debriefing questionnaire, &quot;After MID task&quot; questionnaire.&#xD;
           Approximately 3 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI BOLD signal differences between groups - in Stroop task</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
    <description>BOLD signal Neutral and Emotional blocks, and for Congruent and Incongruent trials (order dependent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI signal variations within patient group during Stroop task, depending on level of ADHD symptoms - in Stroop task</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
    <description>BOLD signal Neutral and Emotional blocks, and for Congruent and Incongruent trials (order dependent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction times in Stroop task</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI BOLD signal differences between groups - in Monetary Incentive Delay task (MID)</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
    <description>BOLD signal during anticipation phase of different levels of reward, and BOLD signal during receipt/outcome phase of different levels of reward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI BOLD signal differences within patient group during MID task, depending on level of ADHD symptoms - in MID task</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
    <description>BOLD signal during anticipation phase of different levels of reward, and BOLD signal during receipt/outcome phase of different levels of reward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction times in MID task</measure>
    <time_frame>Acquired during fMRI scan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stop Signal reaction times (SSRT) from Stop Signal Task (SST)</measure>
    <time_frame>Data necessary for estimation of SSRT acquired during fMRI scan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brown-ADD score</measure>
    <time_frame>Acquired from questionnaire at first visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood and Feelings questionnaire</measure>
    <time_frame>Acquired from questionnaire at first visit</time_frame>
    <description>dimensional measurement of depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAI-T score</measure>
    <time_frame>Acquired from questionnaire at first visit</time_frame>
    <description>Measuring anxiety trait level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt's impulsivity scale (BIS)</measure>
    <time_frame>Acquired from questionnaire at first visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAI-S score</measure>
    <time_frame>Baseline, acquired from questionnaire Day 2</time_frame>
    <description>Measuring anxiety state level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepiness score</measure>
    <time_frame>Acquired during MRI scan, on Day 2</time_frame>
    <description>Acquired 6 times in MRI scanner as follows: 1) Before first Stroop session. 2) Between Stroop session 1 and 2. 3) After Stroop session 2. 4) Before first MID session. 5) Between MID session 1 and 2. 6) After MID session 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation score</measure>
    <time_frame>Acquired during MRI scan, on Day 2</time_frame>
    <description>Acquired 6 times in MRI scanner as follows: 1) Before first Stroop session. 2) Between Stroop session 1 and 2. 3) After Stroop session 2. 4) Before first MID session. 5) Between MID session 1 and 2. 6) After MID session 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural MRI data - volume</measure>
    <time_frame>Acquired during MRI scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural MRI data - surface area</measure>
    <time_frame>Acquired during MRI scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural MRI data - thickness</measure>
    <time_frame>Acquired during MRI scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Connectivity (FC)</measure>
    <time_frame>Acquired during resting state MRI scan</time_frame>
    <description>Measuring the FC value between ROIs defined in hypothesis to determine strength of connectivity between these different brain regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Anisotropy (FA) of white matter</measure>
    <time_frame>Acquired during Diffusion Tensor Imaging (DTI) scan</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Emotional Instability Personality Disorder (Borderline Personality Disorder)</condition>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.&#xD;
Interventions:&#xD;
fMRI - Stroop task&#xD;
fMRI - MID task&#xD;
Stop Signal task&#xD;
Structural T1 MRI scan&#xD;
Structural T2 MRI scan&#xD;
DTI MRI scan&#xD;
Resting state MRI scan&#xD;
FEFA 2&#xD;
SCID-II&#xD;
SDQ&#xD;
ASRS&#xD;
AQ&#xD;
TAS-20&#xD;
Raven's SPM&#xD;
Reading ability&#xD;
Ishihara's tests for colour deficiency&#xD;
Additional questionnaire&#xD;
Brown-ADD&#xD;
MFQ&#xD;
STAI-T&#xD;
BIS&#xD;
DAWBA&#xD;
STAI-S&#xD;
Sleepiness rating x 6&#xD;
Motivation rating x 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).&#xD;
Interventions:&#xD;
fMRI - Stroop task&#xD;
fMRI - MID task&#xD;
Stop Signal task&#xD;
Structural T1 MRI scan&#xD;
Structural T2 MRI scan&#xD;
DTI MRI scan&#xD;
Resting state MRI scan&#xD;
FEFA 2&#xD;
SCID-II&#xD;
SDQ&#xD;
ASRS&#xD;
AQ&#xD;
TAS-20&#xD;
Raven's SPM&#xD;
Reading ability&#xD;
Ishihara's tests for colour deficiency&#xD;
Additional questionnaire&#xD;
Brown-ADD&#xD;
MFQ&#xD;
STAI-T&#xD;
BIS&#xD;
DAWBA&#xD;
STAI-S&#xD;
Sleepiness rating x 6&#xD;
Motivation rating x 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fMRI - Stroop task</intervention_name>
    <description>2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fMRI - MID task</intervention_name>
    <description>2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stop Signal Task</intervention_name>
    <description>Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SCID-II</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SDQ</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ASRS</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AQ</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAS-20</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Raven's SPM</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reading ability</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ishihara's tests for colour deficiency</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional questionnaire</intervention_name>
    <description>including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brown-ADD</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MFQ</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STAI-T</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BIS</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DAWBA</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STAI-S</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleepiness rating</intervention_name>
    <description>Acquired 6 times while in MRI-scanner. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Motivation rating</intervention_name>
    <description>Acquired 6 times while in MRI-scanner. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>FEFA2</intervention_name>
    <description>Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Structural T1 MRI scan</intervention_name>
    <description>See Detailed Study Description and Outcome Measures.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Structural T2 MRI scan</intervention_name>
    <description>See Detailed Study Description.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DTI MRI scan</intervention_name>
    <description>See Detailed Study Description and Outcome Measures.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resting state MRI scan</intervention_name>
    <description>See Detailed Study Description and Outcome Measures.</description>
    <arm_group_label>EIP</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergone puberty&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Monophasic contraceptives&#xD;
&#xD;
          -  Speak Swedish fluently&#xD;
&#xD;
        Additional inclusion criteria EIP patients:&#xD;
&#xD;
        ≥4/9 criteria of DSM-IV, measured by SCID-II interview&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired vision &gt; +/- 5 D or other vision problem (squinting or severe astigmatism)&#xD;
&#xD;
          -  BMI &lt;17, BMI &gt;35 due to possible hormonal disturbance&#xD;
&#xD;
          -  Some medical drugs: benzodiazepines, neuroleptics, mood stabilisers, central&#xD;
             stimulants, other neuro pharmaceuticals. (SSRIs are ok)&#xD;
&#xD;
          -  Not suitable for MRI scan (metal implants or severe claustrophobia)&#xD;
&#xD;
          -  AQ-score &gt;26&#xD;
&#xD;
          -  Alexithymia (≥52 in TAS20 questionnaire or poor score in facial recognition test&#xD;
             (FEFA2));&#xD;
&#xD;
          -  Mental retardation (IQ &lt;70 according to Ravens SPM)&#xD;
&#xD;
          -  Reading difficulties (reading speed &gt;2 standard deviations slower than normal&#xD;
             population of same age&#xD;
&#xD;
          -  Established addiction problems (nicotine ok)&#xD;
&#xD;
          -  Color blindness (&gt;10 points on Ishihara-test)&#xD;
&#xD;
          -  Psychotic disorder (according to medical history, DAWBA, medical records)&#xD;
&#xD;
          -  Anorexia nervosa that has required hospital care&#xD;
&#xD;
          -  Bipolar disorder (according to DAWBA and medical records)&#xD;
&#xD;
          -  Neurological disease (according to medical history and medical records)&#xD;
&#xD;
          -  Endocrinological disease&#xD;
&#xD;
          -  Other disease, condition or treatment that may substantially affect cognition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Predrag Petrovic</last_name>
    <email>predrag.petrovic@ki.se</email>
  </overall_contact>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Predrag Petrovic</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

